Previous 10 | Next 10 |
AAOI , AIMT , AKCA , ALB , ANGI , APLE , ARNA , ASRT , AXGN , BIO , BREW , CCMP , CECO , CNDT , COLL , CPA , CTL , CVNA , CW , CWH , CXW , DAR , DHT , DIS , DRH , DVAX , ECPG , EGAN , ELF , ENV , ET , ETSY , EVRG , EZPW , FLNT , FNV , FOSL , FOXA , FTK...
AxoGen (NASDAQ: AXGN ) is scheduled to announce Q1 earnings results on Wednesday, May 8th, after market close. More news on: AxoGen, Inc., Earnings news and commentary, , Healthcare stocks news, Read more ...
Quentin S. Blackford, Executive Vice President and Chief Financial Officer of Dexcom Alan M. Levine Chairman, President, and Chief Executive Officer for Ballad Health New members bring a breadth of healthcare leadership experience to the Axogen Board of Directors ALACHUA, Fl...
Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Novartis ( NVS ): The stock has been tumbling after the company announced interim data from the Phase 2 STR1VE trial of Zolgensma/AVXS-101 in spinal muscular atrophy ( SMA ) Type 1. While it's true that prolonged event-free survival and rapid increase in CHOP-INTEND scores were encouragi...
AxoGen (NASDAQ: AXGN ) announces that, based on a pre-planned interim analysis on the first 80 subjects, its Phase 3 clinical trial, RECON , evaluating its Avance Nerve Graft compared to synthetic conduits for the repair of nerve injuries in the hand will continue as planned with an incre...
ALACHUA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced completion of the planned blinded interim analysis for its RECON Study. Th...
ALACHUA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2019 financial results on Wednesday, May...
ALACHUA, Fla., March 04, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that members of its management team will participate in three investor con...
AxoGen, Inc. (AXGN) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Kaila Krum - Vice President, Investor Relations & Corporate Development Karen Zaderej - Chairman, Chief Executive Officer & President Pete Mariani - Chief Financial Offi...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...